Genetic profile of patients with stage I–IIIA non-small cell lung cancer
https://doi.org/10.17650/1726-9784-2023-22-1-42-48
Abstract
Background. The article presents data on somatic mutations found in the Russian population of patients with non-small cell lung cancer (NSCLC), their frequency, distribution depending on the histological type of tumor.
Aim. To study the molecular genetic profile of Russian patients with stage I–IIIA localized NSCLC, the frequency of occurrence of various somatic mutations, variants of the switching status.
Materials and methods. Genetic testing for a panel of 78 genes using the Next Generation Sequencing method of tumor material obtained after surgical treatment of 65 patients with localized stage I–IIIA NSCLC. Processing of the received data was carried out by methods of descriptive statistics.43
Results. Mutations in the EGFR, ALK, ROS1, RET, BRAF, KRAS, MET, HER2 genes were found only in adenocarcinoma. Among non-targeted mutations in adenocarcinoma, TP53, STK11, FGFR3, EML4, NF1, RB1, and KMTC2 mutations were the most common. In squamous cell lung cancer, TP53, KMT2C, TSC1, EML4, PTEN, NF1, COL22A1, CDKN2A, RB1, BRCA1 were the most common. Mutations in the EGFR gene were most often associated with mutations in TP53 (30 % of cases), RB1 (15 % of cases), COL22A1 (15 % of cases); ALK was combined with TP53, NF1, WT1 – in 33 % of cases, ROS1 with DDR2 (33 % of cases), ERBB2 was combined with NTRK1, GPC3, HIP1, KIF5B, TP53, XPC, COL22A1 – in 14 % of cases, BRAF was most often associated with mutations in the TP53 gene (14 %) and COL22A1 (13.8 %); a mutation in the RET gene was associated with a TP53 mutation; ROS1 translocation in 50 % of cases was associated with mutations in the TRIM33 and TP53 genes.
Conclusion. The data obtained give an idea of the frequency of occurrence of somatic mutations among Russian patients with NSCLC, which is important for the selection of diagnostic panels, interpretation of their results, and also potentially for the development of original custom Next Generation Sequencing testing panels.
About the Authors
A. M. Kazakov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Alexey Mikhailovich Kazakov
24 Kashirskoe Shosse, Moscow 1154522, Russia
K. K. Laktionov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia;
Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 1154522, Russia
1 Ostrovityanova St., Moscow 117997, Russia
K. A. Sarantseva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 1154522, Russia
References
1. Malignant neoplasms in Russia in 2021 (morbidity and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, A.O. Shakhza dova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).
2. Noor Z.S., Cummings A.L., Johnson M.M. et al. Targeted therapy for non-small cell lung cancer. Semin Respir Crit Care Med 2020;41(3):409–34. DOI: 10.1055/s-0039-1700994
3. Laktionov K.K., Artamonova E.V., Breder V.V. et al. Practical recommendations for the drug treatment of non-small cell lung cancer. Zlokachestvennye opukholi: Prakticheskie rekomendatsii RUSSCO = Malignant tumors: RUSSCO Practical Guidelines 2022;12:41–59. (In Russ.). DOI: 10.18027/2224-5057-2020-10-3s2-02
4. Wu Y.-L., Tsuboi M., He J. et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med 2020;383(18):1711–23. DOI: 10.1056/NEJMoa2027071
5. Chu Q.S. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion. Ther Adv Med Oncol 2020;12:1758835919895756. DOI: 10.1177/1758835919895756
6. Vnencak-Jones C., Berger M., Pao W. Types of molecular tumor testing. My Cancer Genome 2016. Available at: https://www.mycancergenome.org/content/molecular-medicine/types-of-molecular-tumor-testing
7. Melosky B., Kambartel K., Häntschel M. et al. Worldwide prevalence of epidermal growth factor receptor mutations in nonsmall cell lung cancer: a meta-analysis. Mol Diagn Ther 2022;26(1):7–18. DOI: 10.1007/s40291-021-00563-1
8. Jazieh A.R., Gaafar R., Errihani H. et al. Real-world data on the prevalence of anaplastic lymphoma kinase-positive nonsmall-cell lung cancer in the Middle East and North Africa. JCO Glob Oncol 2021;7:1556–63. DOI: 10.1200/GO.21.00067
9. O’Leary C.G., Andelkovic V., Ladwa R. et al. Targeting BRAF mutations in non-small cell lung cancer. Transl Lung Cancer Res 2019;8(6):1119–24. DOI: 10.21037/tlcr.2019.10.22
10. Liu S., Yu J., Zhang H., Liu J. TP53 co-mutations in advanced EGFR-mutated non-small cell lung cancer: prognosis and therapeutic strategy for cancer therapy. Front Oncol 2022;12:860563. DOI: 10.3389/fonc.2022.860563
11. Adderley H., Blackhall F.H., Lindsay C.R. KRAS-mutant nonsmall cell lung cancer: converging small molecules and immune checkpoint inhibition. EBioMedicine 2019;41:711–16. DOI: 10.1016/j.ebiom.2019.02.049
12. Shire N.J., Klein A.B., Golozar A. et al. STK11 (LKB1) mutations in metastatic NSCLC: prognostic value in the real world. PLoS One 2020;15(9):e0238358. DOI: 10.1371/journal.pone.0238358
13. Huang Q., Li F., Hu H. et al. Loss of TSC1/TSC2 sensitizes immune checkpoint blockade in non-small cell lung cancer. Sci Adv 2022;8(5):eabi9533. DOI: 10.1126/sciadv.abi9533
Review
For citations:
Kazakov A.M., Laktionov K.K., Sarantseva K.A. Genetic profile of patients with stage I–IIIA non-small cell lung cancer. Russian Journal of Biotherapy. 2023;22(1):42-48. (In Russ.) https://doi.org/10.17650/1726-9784-2023-22-1-42-48
Views:
287
Email this article 
